News | June 09, 2021
Glenmark's interim data from PMS Study on Favipiravir released
The study was conducted in patients with mild to moderate COVID-19
The study was conducted in patients with mild to moderate COVID-19
Production line at Lonza’s site in Geleen will complement the existing production network and support the manufacture of up to an additional 300 million doses per year
It is expected that the drug substance would be available from August 2021 which will be supplied back to Bharat Biotech for producing COVAXIN
Financial support is being provided as a grant from the Government of India
The country has constantly worked with the spirit of public-private partnership
The current production capacity of indigenously developed Covaxin vaccine will be doubled by May-June 2021 and then increased nearly 6-7 fold by July-August 2021.
The merger is in line with Solara’s strategy of accelerating growth via appropriate inorganic actions
India produces 60% of the world’s vaccine
Report outlines the wide array of investment opportunities in various segments of India’s healthcare sector
The company will add a single-use assembly production unit at its Life Science Center in Molsheim, France.
Subscribe To Our Newsletter & Stay Updated
